OTC Markets OTCPK - Delayed Quote USD

Scancell Holdings plc (SCNLF)

Compare
0.1800
0.0000
(0.00%)
At close: January 10 at 3:00:00 PM EST
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
4/30/2024
4/30/2023
4/30/2022
4/30/2021
Total Revenue
--
--
5,271.0000
--
--
Cost of Revenue
--
--
525.0000
--
--
Gross Profit
--
--
4,746.0000
--
--
Operating Expense
18,267.0000
18,267.0000
16,666.0000
13,299.0000
8,834.0000
Operating Income
-18,267.0000
-18,267.0000
-11,920.0000
-13,299.0000
-8,834.0000
Net Non Operating Interest Income Expense
-734.0000
-734.0000
-931.0000
-1,773.0000
-7,971.0000
Pretax Income
-9,117.0000
-9,117.0000
-14,304.0000
-6,272.0000
-16,805.0000
Tax Provision
-3,258.0000
-3,258.0000
-2,368.0000
-1,703.0000
-1,328.0000
Net Income Common Stockholders
-5,859.0000
-5,859.0000
-11,936.0000
-4,569.0000
-15,477.0000
Average Dilution Earnings
-8,853.0000
-8,853.0000
--
--
--
Diluted NI Available to Com Stockholders
-14,712.0000
-14,712.0000
-11,936.0000
-4,569.0000
-15,477.0000
Basic EPS
-0.01
-0.01
-0.01
-0.00
-0.02
Diluted EPS
-0.01
-0.01
-0.01
-0.00
-0.02
Basic Average Shares
818,271.6040
862,484.4300
816,051.3110
815,535.4200
678,892.3250
Diluted Average Shares
819,981.7760
1,029,794.4650
816,051.3110
815,535.4200
678,892.3250
Total Operating Income as Reported
-18,267.0000
-18,267.0000
-11,920.0000
-13,299.0000
-8,834.0000
Rent Expense Supplemental
123.0000
--
--
--
--
Total Expenses
18,267.0000
18,267.0000
17,191.0000
13,299.0000
8,834.0000
Net Income from Continuing & Discontinued Operation
-5,859.0000
-5,859.0000
-11,936.0000
-4,569.0000
-15,477.0000
Normalized Income
-12,210.9092
-12,210.9092
-10,723.5414
-10,979.5867
-15,477.0000
Interest Income
355.0000
355.0000
284.0000
4.0000
3.0000
Interest Expense
1,089.0000
1,089.0000
1,215.0000
1,777.0000
1,651.0000
Net Interest Income
-734.0000
-734.0000
-931.0000
-1,773.0000
-7,971.0000
EBIT
-8,028.0000
-8,028.0000
-13,089.0000
-4,495.0000
-15,154.0000
EBITDA
-7,062.0000
-7,062.0000
-12,187.0000
-3,755.0000
-14,905.0000
Reconciled Cost of Revenue
--
--
525.0000
--
--
Reconciled Depreciation
966.0000
966.0000
902.0000
740.0000
249.0000
Net Income from Continuing Operation Net Minority Interest
-5,859.0000
-5,859.0000
-11,936.0000
-4,569.0000
-15,477.0000
Total Unusual Items Excluding Goodwill
9,884.0000
9,884.0000
-1,453.0000
8,800.0000
--
Total Unusual Items
9,884.0000
9,884.0000
-1,453.0000
8,800.0000
--
Normalized EBITDA
-16,946.0000
-16,946.0000
-10,734.0000
-12,555.0000
-14,905.0000
Tax Rate for Calcs
0.0004
0.0004
0.0002
0.0003
0.0001
Tax Effect of Unusual Items
3,532.0908
3,532.0908
-240.5414
2,389.4133
--
4/30/2021 - 8/2/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SBMJF Dimerix Limited
0.2650
0.00%
 
6XP.SG Xspray Pharma AB (publ)
2.9600
-6.03%
 
4YL.F Nanoform Finland Oyj
1.2720
-2.90%
 
0M4.F Mersana Therapeutics, Inc.
0.8396
-29.53%
 
XSPRAY.ST Xspray Pharma AB (publ)
29.25
-15.34%
 
5CV.DE CureVac N.V.
4.2660
+9.61%
 
CARA Cara Therapeutics, Inc.
4.7500
0.00%
 
MRSN Mersana Therapeutics, Inc.
0.7200
-44.62%
 
JAGX Jaguar Health, Inc.
1.0000
-8.26%